BMO Capital analyst Etzer Darout initiated coverage of AstraZeneca with an Outperform rating and $82 price target. AstraZeneca is a leader in pharmaceutical drug development, "buoyed by its diverse portfolio" of products in oncology, rare disease, and biopharmaceutical segments, Darout tells investors in a research note. The analyst says the company’s growth and margin expansion are undervalued relative to peers as it continues to migrate to higher-margin programs.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AZN:
- Kymera Therapeutics appoints Chiniara as CLO, Corporate Secretary
- AstraZeneca price target raised to 13,500 GBp from 12,500 GBp at JPMorgan
- AstraZeneca announces Calquence approved in Japan to treat CLL
- AstraZeneca announces Imfinzi, Imjudo approved in Japan to treat three cancers
- AstraZeneca’s Lynparza approved in E.U. as first line treatment in mCRPC